According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.8% and a 52.68% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis ...

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Novartis AG (NYSE:NVS) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. On June 12, Berenberg Bank analyst ...

Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF104.00. The company’s shares cl ...

Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...

In its first-quarter 2025 investor letter, Loomis Sayles Global Growth Fund highlighted stocks such as Novartis AG (NYSE:NVS). Novartis AG (NYSE:NVS) is a pharmaceutical company that engages in the ...

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...

Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.

and other risks and factors referred to in Novartis AG's and Regulus's filings and reports with the SEC, including Novartis AG's Annual Report on Form 20-F for the year ended December 31 ...